Literature DB >> 24550516

Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.

Michael C Burns1, Qi Sun, R Nathan Daniels, DeMarco Camper, J Phillip Kennedy, Jason Phan, Edward T Olejniczak, Taekyu Lee, Alex G Waterson, Olivia W Rossanese, Stephen W Fesik.   

Abstract

Aberrant activation of the small GTPase Ras by oncogenic mutation or constitutively active upstream receptor tyrosine kinases results in the deregulation of cellular signals governing growth and survival in ∼30% of all human cancers. However, the discovery of potent inhibitors of Ras has been difficult to achieve. Here, we report the identification of small molecules that bind to a unique pocket on the Ras:Son of Sevenless (SOS):Ras complex, increase the rate of SOS-catalyzed nucleotide exchange in vitro, and modulate Ras signaling pathways in cells. X-ray crystallography of Ras:SOS:Ras in complex with these molecules reveals that the compounds bind in a hydrophobic pocket in the CDC25 domain of SOS adjacent to the Switch II region of Ras. The structure-activity relationships exhibited by these compounds can be rationalized on the basis of multiple X-ray cocrystal structures. Mutational analyses confirmed the functional relevance of this binding site and showed it to be essential for compound activity. These molecules increase Ras-GTP levels and disrupt MAPK and PI3K signaling in cells at low micromolar concentrations. These small molecules represent tools to study the acute activation of Ras and highlight a pocket on SOS that may be exploited to modulate Ras signaling.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24550516      PMCID: PMC3948241          DOI: 10.1073/pnas.1315798111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

Authors:  Herbert Waldmann; Ioanna-Maria Karaguni; Mercedes Carpintero; Eleni Gourzoulidou; Christian Herrmann; Christoph Brockmann; Hartmut Oschkinat; Oliver Müller
Journal:  Angew Chem Int Ed Engl       Date:  2004-01-16       Impact factor: 15.336

2.  Structural analysis of autoinhibition in the Ras activator Son of sevenless.

Authors:  Holger Sondermann; Stephen M Soisson; Sean Boykevisch; Shao-Song Yang; Dafna Bar-Sagi; John Kuriyan
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

3.  Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements.

Authors:  C Lenzen; R H Cool; A Wittinghofer
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

5.  Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.

Authors:  B E Hall; S S Yang; P A Boriack-Sjodin; J Kuriyan; D Bar-Sagi
Journal:  J Biol Chem       Date:  2001-05-01       Impact factor: 5.157

Review 6.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

7.  A Ras-induced conformational switch in the Ras activator Son of sevenless.

Authors:  Tanya S Freedman; Holger Sondermann; Gregory D Friedland; Tanja Kortemme; Dafna Bar-Sagi; Susan Marqusee; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

8.  The structural basis of the activation of Ras by Sos.

Authors:  P A Boriack-Sjodin; S M Margarit; D Bar-Sagi; J Kuriyan
Journal:  Nature       Date:  1998-07-23       Impact factor: 49.962

9.  Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism.

Authors:  Elena Mossessova; Richard A Corpina; Jonathan Goldberg
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

10.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

View more
  66 in total

Review 1.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

Review 2.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

3.  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.

Authors:  Chaoxin Hu; Tikva Dadon; Venugopal Chenna; Shinichi Yabuuchi; Rajat Bannerji; Robert Booher; Peter Strack; Nilofer Azad; Barry D Nelkin; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2015-04-30       Impact factor: 6.261

4.  Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.

Authors:  Chris R Evelyn; Xin Duan; Jacek Biesiada; William L Seibel; Jaroslaw Meller; Yi Zheng
Journal:  Chem Biol       Date:  2014-11-20

Review 5.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

6.  Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.

Authors:  Chris R Evelyn; Jacek Biesiada; Xin Duan; Hong Tang; Xun Shang; Ruben Papoian; William L Seibel; Sandra Nelson; Jaroslaw Meller; Yi Zheng
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

Review 7.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

8.  Regulation of the Small GTPase Ras and Its Relevance to Human Disease.

Authors:  Kayla R Kulhanek; Jeroen P Roose; Ignacio Rubio
Journal:  Methods Mol Biol       Date:  2021

9.  Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.

Authors:  Russell Spencer-Smith; Lie Li; Sheela Prasad; Akiko Koide; Shohei Koide; John P O'Bryan
Journal:  Small GTPases       Date:  2017-12-31

10.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.